ERYTECH Pharma S.A.
Develops red blood cell-based therapies for cancer and orphan diseases.
ERYP | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417360 (+2 more)
- LEI:
- 969500U8ZZCODU8A9374
- Country:
- France
- Address:
- 60 AVENUE ROCKEFELLER, 69008 LYON
- Website:
- https://phaxiam.com/
- Sector:
- Manufacturing
Description
ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-05-26 22:00 |
Erytech’s Combined Shareholders’ Meeting
|
English | 739.9 KB | ||
| 2020-05-06 22:30 |
ERYTECH Provides Business Update and Reports Cash Balance at End of Q1 2020
|
English | 693.9 KB | ||
| 2020-02-26 23:00 |
ERYTECH to Present at Cowen and Company 40th Annual Health Care Conference
|
English | 239.0 KB | ||
| 2020-02-26 23:00 |
ERYTECH annonce sa participation à la 40ème conférence Santé de Cowen
|
French | 253.2 KB | ||
| 2020-02-20 22:30 |
ERYTECH annonce la signature d’un partenariat stratégique d'approvisionnement a…
|
French | 231.5 KB | ||
| 2020-02-20 22:30 |
ERYTECH Enters Into Strategic Supply Partnership with the German Red Cross Bloo…
|
English | 219.0 KB | ||
| 2020-02-04 18:00 |
Information mensuelle relative au nombre total de droits de vote et d’actions c…
|
French | 194.4 KB | ||
| 2020-02-04 18:00 |
Monthly information related to total number of voting rights and shares composi…
|
English | 172.2 KB | ||
| 2020-01-24 07:30 |
ERYTECH présente un poster sur TRYbeCA1 lors du symposium ASCO 2020
|
French | 747.0 KB | ||
| 2020-01-24 07:30 |
ERYTECH Announces a Poster Presentation for TRYbeCA1 at the ASCO 2020
|
English | 625.1 KB | ||
| 2020-01-10 17:45 |
Information mensuelle relative au nombre total de droits de vote et d’actions c…
|
French | 220.0 KB | ||
| 2020-01-10 17:45 |
Monthly information related to total number of voting rights and shares composi…
|
English | 200.2 KB | ||
| 2019-12-02 18:00 |
Monthly information related to total number of voting rights and shares composi…
|
English | 199.3 KB | ||
| 2019-12-02 18:00 |
Information mensuelle relative au nombre total de droits de vote et d’actions c…
|
French | 218.4 KB | ||
| 2019-11-25 07:30 |
ERYTECH Announces Publication of its Phase 2b Trial of Eryaspase in Metastatic …
|
English | 744.8 KB |
Automate Your Workflow. Get a real-time feed of all ERYTECH Pharma S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ERYTECH Pharma S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ERYTECH Pharma S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-06-23 | N/A | Other | Other | 3,697,533 | 2,255,495.13 EUR |
| 2023-06-23 | N/A | Other | Other | 71,839 | 43,821.79 EUR |
| 2023-06-23 | N/A | Other | Other | 54,862 | 33,465.82 EUR |
Peer Companies
